Reply to Sharma et al and Saukkonen et al

Clinical Infectious Diseases

Volumn 51, Issue 2, 2010, Pages 255-

  Heller, T ^a   Wallrauch, C ^b   Lessells, R J ^b  

^a Hlabisa Hospital   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; TOXIC HEPATITIS; TUBERCULOSIS; AFRICA SOUTH OF THE SAHARA;

AFRICA SOUTH OF THE SAHARA; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS; TUBERCULOSIS;

EID: 77954697538     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653682     Document Type: Letter

References (6)

1. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50:833-839.
2. Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010; 50:840-842.
3. South Africa Department of Health. The South African National Tuberculosis Control Programme practical guidelines. Pretoria, South Africa: South Africa Department of Health; 2004.
4. Hoffmmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
5. Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut 1972; 13:366-371.
6. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-952.